Conference News

Get Ready for CPHI: Off-Patent Semaglutide and Sustainability in a Shifting World

It’s showtime in Frankfurt – with around 62,000 attendees expected.

  • October 27, 2025

  • 5 min

Share

8 Key Takeaways

  • 1

    CPHI Frankfurt starts with over 2,400 exhibitors.

  • 2

    Keynote focuses on sustainability in packaging.

  • 3

    Semaglutide loses exclusivity in 202

  • 4

    FDA challenges discussed regarding 483s.

  • 5

    Festhalle has a complex historical significance.

  • 6

    Event Director Tara Dougal will be highlighted.

  • 7

    Continuous manufacturing is a panel theme.

  • 8

    Jim Macguire discusses obesity complexities.

Related Content

Plozasiran Wins FDA Nod for FCS

Arrowhead’s small interfering RNA therapy reduced triglycerides and lowered pancreatitis risk in the phase 3 PALISADE trial, providing a quarterly self-administered option for patients with familial chylomicronemia syndrome.

Should SGLT-2 Inhibitors Be Continued After a UTI?

Patients with type 2 diabetes who developed urinary tract infections while taking sodium-glucose cotransporter-2 inhibitors faced higher heart and kidney risks.

Can SGLT-2 Inhibitors Shield Against Autoimmune Disease?

Researchers found sodium-glucose cotransporter-2 inhibitors lowered autoimmune rheumatic disease risk by 11% in adults with type 2 diabetes.